Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN Net Income

Bottom-line profit after all expenses, interest, and taxes.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income turns positive

Q4 FY2025 net income was $3.04M, compared with -$1.32M a year earlier. Over 3 fiscal years it compounded at -10.3% a year.

Context

  • Net income amounted to 74.1% of revenue in FY2025, up 45.1 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$3.04M— QoQ
Last fiscal yearDec 2025
$7.23M+204.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+329.4%——
1 year+204.6%——
3-year CAGR-10.3%——
5-year CAGR——
10-year CAGR——

Net Income history

USD · from the income statement

Latest · FY2025
7.23M USD
Year-over-year change
+204.6%
4-year CAGR
+29.9%

Net Income vs competitors

How NNNN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +204.6% is the 3rd highest of 10, against a peer median of +81.9%.
  • Net income amounts to 74.1% of revenue for NNNN, versus a peer median of 10.0%.
NNNN Competitors
Net Income for NNNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$364.23M USD+879.7%—121.5%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$7.23M USD+204.6%-10.3%74.1%
TALKTalkspace, Inc.LTM Mar 2026$1.17M USD+281.8%—0.5%
SNDLSNDL Inc.LTM Mar 2026-CA$10.98M CAD+89.7%—1.2%
CLPTClearPoint Neuro, Inc.LTM Mar 2026-$29.07M USD-39.8%—71.6%
ANGOAngioDynamics, Inc.LTM Feb 2026-$31.39M USD+24.2%—10.0%
AVNSAvanos Medical, Inc.LTM Mar 2026-$69.4M USD+82.0%—9.7%
CYHCommunity Health Systems, Inc.LTM Mar 2026-$88M USD+81.9%+122.8%0.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-$138.44M USD——119.4%
CMPSCOMPASS Pathways plcLTM Mar 2026-$178.95M USD-29.9%——
GOSSGossamer Bio, Inc.LTM Mar 2026-$180.4M USD-252.1%—324.8%
Peer median (excluding NNNN) —+81.9%+122.8%10.0%

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.43M23.54M6.71M8.19M9.76M
Cost of Revenue1.89M10.98M3.35M2.3M1.25M
Gross Profit2.54M12.56M3.36M5.89M8.51M
Gross Margin57.4%53.4%50.1%71.9%87.2%
Research & Development0200K134.7K454.23K227.19K
Selling, General & Admin86.1K2.17M1.27M3.44M1.78M
Operating Expenses86.1K2.37M1.4M3.89M2M
Depreciation & Amortization06.25K13.04K00
EBITDA2.54M10.03M2.27M2.57M6.51M
EBITDA Margin57.3%42.6%33.8%31.4%66.7%
Operating Income2.46M10.2M1.96M2M6.51M
Operating Margin55.5%43.3%29.2%24.4%66.7%
Interest Income042.25K165.34K337.51K160.28K
Interest Expense08K000
Other Income / Expenses79.94K(184.41K)292.78K377.48K717.46K
Income Before Tax2.54M10.01M2.25M2.37M7.23M
Pre-Tax Margin57.3%42.5%33.6%29.0%74.1%
Income Tax Expense00000
Net Income2.54M10.01M2.25M2.37M7.23M
Net Margin57.3%42.5%33.6%29.0%74.1%
EPS (Basic)0.030.070.020.060.16
EPS (Diluted)0.030.070.010.060.16
Weighted Avg Shares100M143.89M143.89M42.29M43.89M
Weighted Avg Shares (Diluted)100M143.89M187.78M42.29M43.89M

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.